SUCLA2-related mitochondrial DNA depletion syndrome
Acesse agora, gratuitamente, o National Institutes of Health e consulte, com o suporte da inteligência artificial do ProtoMedi, informações técnicas detalhadas sobre este e outros medicamentos. Obtenha respostas rápidas e confiáveis sobre interações, indicações e precauções — no momento em que você mais precisa
Dados do National Institutes of Health
| SUCLA2-related mitochondrial DNA depletion syndrome : SUCLA2-related mitochondrial DNA (mtDNA) depletion syndrome is an inherited disorder that affects the early development of the brain. Affected infants typically develop weak muscle tone (hypotonia) in the first few months of life. In these infants, hypotonia can delay the development of motor skills such as lifting the head and rolling over. Children with SUCLA2-related mtDNA depletion syndrome typically have difficulty eating and may require a feeding tube; as a result, they have difficulty growing and gaining weight as expected (failure to thrive). Additional features of SUCLA2-related mtDNA depletion syndrome can include uncontrolled movements (dystonia), hearing loss, muscle wasting (atrophy), and intellectual disabilities. In most affected children, a substance called methylmalonic acid builds up in the blood. People with SUCLA2-related mtDNA depletion syndrome typically have a shortened lifespan. Approximately 30 percent of individuals with SUCLA2-related mtDNA depletion syndrome do not survive past childhood. | |
| Review Date: 19/07/2024 | Updated By: |